MENINGVAX / VACCINE TECHNOLOGIES / 020
Vaccine Platforms
Comparing the molecular strategies used to induce immunity against meningitis-causing bacteria—and the technologies shaping future vaccine research.
01 / TECHNOLOGY COMPARISON
Three established vaccine strategies
Vaccine platforms differ in antigen composition, immune mechanisms, and development constraints. Their use depends on the pathogen and the evidence supporting each product.
Polysaccharide conjugates
A bacterial capsular polysaccharide is chemically linked to a carrier protein to promote T-cell-dependent antibody responses.
Examples: MenACWY, Hib, pneumococcal conjugatesRecombinant proteins
Selected microbial proteins are produced using recombinant expression systems and formulated as vaccine antigens.
Examples: fHbp-containing MenB vaccinesOuter membrane vesicles
Nanoscale bacterial membrane-derived vesicles display multiple antigens and can stimulate innate and adaptive immune responses.
Example: OMV components in certain MenB vaccines02 / SCIENTIFIC DEVELOPMENT
Platform selection is pathogen-specific
For meningococcal serogroups A, C, W, and Y, capsular conjugate vaccines are central preventive tools. MenB vaccines instead rely on protein antigens, sometimes combined with outer membrane vesicles.
Important development considerations include antigen diversity, functional antibody responses, formulation consistency, safety, and population-level effectiveness.
Can platforms support broader protection?
Research investigates engineered antigens and vesicle-based formulations to expand strain coverage. Proposed improvements require experimental and clinical confirmation.
Peer-reviewed references
- Outer membrane vesicles as platform vaccine technology. PubMed ↗
- Outer Membrane Vesicle Vaccine Platforms. PubMed ↗
- Novel approaches to Neisseria meningitidis vaccine design. PubMed ↗
- Vaccines against meningococcal serogroup B disease containing outer membrane vesicles: lessons from past programs. PubMed ↗